aTyr Pharma Phase 3 efzofitimod Study Misses Primary Endpoint, Shows PRO Benefits

aTyr Pharma (ATYR) published Phase 3 EFZO-FIT results in The Lancet Respiratory Medicine. The trial of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint of steroid dose reduction at week 48. It improved multiple patient-reported outcomes, maintained lung function, and was well-tolerated. The company is advancing a new Phase 3 study in pulmonary sarcoidosis and a Phase 2 study in scleroderma-related ILD.